Duchenne Muscular Dystrophy Treatment Landscape Enters a Defining Phase as Gene Therapy and Exon-Skipping Pipelines Mature | Thelansis

Thelansis maps the competitive field, unmet needs, and Target Product Profile expectations shaping the next decade of DMD drug development

Executive Summary
Duchenne muscular dystrophy (DMD) - a rare, X-linked neuromuscular disorder caused by loss of functional dystrophin - has moved from a field defined largely by supportive care to one increasingly shaped by gene therapy, exon-skipping chemistries, and gene-editing approaches. With an estimated incidence of roughly 1 in 3,600 male live births and U.S. prevalence near 2 per 10,000 males, DMD remains one of the most closely watched rare disease categories among pharmaceutical and biotech strategy teams. Several emerging assets are nearing pivotal readouts or regulatory milestones through 2026, prompting patient advocacy groups to describe this as one of the most consequential years yet for the DMD community.

Against this backdrop, Thelansis' Duchenne Muscular Dystrophy (DMD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 examines how the competitive landscape, unmet needs, and physician/KOL expectations are evolving across the G8 markets, offering a structured view of where commercial opportunity is concentrating.

Request a free sample of Thelansis' Duchenne Muscular Dystrophy (DMD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026: https://thelansis.com/reports/duchenne-muscular-dystrophy-dmd-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/

Key Current Therapies and Standard of Care
Corticosteroids remain the backbone of standard care for slowing functional decline, supplemented in recent years by approved exon-skipping antisense oligonucleotides and the first commercially available microdystrophin gene therapy. Recent long-term data presented at major neuromuscular congresses continue to reinforce dystrophin restoration as a foundational treatment strategy, with multi-year follow-up suggesting a meaningful slowing of disease progression relative to natural history and external control cohorts.

• Corticosteroid therapy - disease-modifying standard of care, though associated with long-term tolerability trade-offs
• Exon-skipping antisense oligonucleotides - approved for specific mutation-amenable patient subsets (exons 51, 53, 45)
• AAV-based microdystrophin gene therapy - the first one-time gene therapy approved for ambulatory and, more recently, expanded age populations
• Multidisciplinary supportive care - cardiology, pulmonology, and physical therapy remain essential adjuncts across all treatment lines

Key Emerging Players Driving Pipeline Momentum
The emerging competitive set spans gene editing, next-generation exon skipping, and mutation-specific oligonucleotide platforms, with more than 100 pipeline assets and over 50 companies tracked across the global development landscape.

• Next-generation gene editing - companies pursuing AAV-delivered gene excision approaches have recently cleared regulatory milestones enabling first-in-human studies, positioning a mechanism distinct from existing microdystrophin and exon-skipping modalities
• Exon 44-targeted oligonucleotides - early-phase data has shown encouraging dystrophin production and reductions in creatine kinase, a key muscle-damage biomarker, in a patient subset with historically no approved option
• Exon 53-targeted candidates - mid-stage interim data has shown consistent dystrophin expression alongside favorable safety, reinforcing competitive interest in this exon class
• Pivotal-stage gene therapy programs - manufacturing scale-up and enrollment completion milestones signal multiple late-stage assets converging toward potential filings in the next
12-24 months

Eligibility criteria for gene-based therapies also continue to evolve. Exclusion zones tied to immunogenicity risk are narrowing as more real-world experience accumulates, and age-based access has recently expanded, a trend with direct implications for addressable patient populations and TPP design.

Secure your position in the emerging DMD market by unlocking the critical pipeline benchmarks and TPP data driving the field forward. Request a Sample: https://thelansis.com/reports/duchenne-muscular-dystrophy-dmd-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dmd_tpp

Key Unmet Need and KOL Expectations
Despite recent progress, physicians and caregivers continue to highlight gaps that next-generation therapies have yet to fully close. KOL feedback consistently points to a need for broader mutation coverage, particularly for exon classes that remain without an approved option, along with greater clarity on outcomes in older, non-ambulatory, and previously excluded patient subgroups.
• Durable, disease-modifying benefit extending into non-ambulatory stages of disease
• Therapies addressing cardiac and pulmonary decline, not muscle function alone
• Reduced immunogenicity risk and broader AAV-eligibility for redosing or sequential therapy
• Mutation coverage for exon classes still lacking an approved targeted therapy
• Clearer long-term, real-world data to guide treatment-line sequencing decisions

Thelansis' TPP framework translates these expectations into quantified attribute preferences and likelihood-to-prescribe scoring, helping development teams benchmark candidate profiles against what physicians say would actually shift practice.

The Thelansis Duchenne Muscular Dystrophy (DMD) report directly addresses these clinical gaps, delivering KOL-validated unmet need assessments, competitive TPP analysis, and the strategic roadmap required for emerging therapies to succeed commercially. Request a Sample: https://thelansis.com/reports/duchenne-muscular-dystrophy-dmd-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dmd_tpp

Commercial Opportunity
As multiple late-stage assets approach potential approval and earlier-stage gene-editing and oligonucleotide candidates advance through clinical development, the DMD competitive set is set to become considerably more differentiated over the next decade. For developers and commercial teams, the strategic questions are shifting from "can we restore dystrophin" to "which mechanism, mutation coverage, and durability profile will define standard of care." Early, data-driven positioning against unmet need and TPP benchmarks will be a key differentiator for both incumbents and new entrants across the G8 markets.

What the Report Delivers
• Detailed emerging competitive landscape - pipeline analysis, target patient segments, mechanisms of action, and launch date estimates
• Clinical trial landscape analysis - target segments, endpoints, trial design, and recruitment criteria
• Unmet needs and opportunity sizing - performance benchmarking of current therapies against top unmet needs
• Target Product Profile (TPP) analysis - attribute-level prescribing likelihood and expected patient share
• KOL insights - awareness, expected line of therapy, and extent of unmet need fulfilment for emerging assets
• G8 market coverage - United States, EU5 (France, Germany, Italy, Spain, U.K.), Japan, and China

Request a free sample report to access primary KOL insights, detailed TPP analysis, and comprehensive competitive data across eight major Duchenne Muscular Dystrophy markets: https://thelansis.com/reports/duchenne-muscular-dystrophy-dmd-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dmd_tpp

Contact
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

About Thelansis
Thelansis Knowledge Partners is a global life sciences market research and consulting firm supporting pharmaceutical, biotechnology, and healthcare companies with specialized market intelligence across epidemiology, competitive landscape, unmet need, market access, and forecasting. Thelansis' rare disease and specialty indication coverage spans neurology, oncology, dermatology, and beyond, helping commercial and strategy teams make evidence-backed portfolio decisions. Learn more at thelansis.com.

This release was published on openPR.